Evaluation of Plaque Stability of Advanced Atherosclerotic Lesions in Apo E-Deficient Mice after Treatment with the Oral Factor Xa Inhibitor Rivaroxaban by Zhou, Qianxing et al.
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2011, Article ID 432080, 9 pages
doi:10.1155/2011/432080
Research Article
EvaluationofPlaque StabilityofAdvanced Atherosclerotic
Lesionsin Apo E-Deﬁcient Mice afterTreatmentwiththeOral
FactorXa InhibitorRivaroxaban
Qianxing Zhou,1,2 FlorianBea,1 Michael Preusch,1 Hongjie Wang,1 BerendIsermann,3
KhurrumShahzad,3 Hugo A. Katus,1 andErwinBlessing1
1Department of Internal Medicine III, University of Heidelberg, 69120 Heidelberg, Germany
2Department of Cardiology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan 430030, China
3Department of Internal Medicine I, University of Heidelberg, 69120 Heidelberg, Germany
Correspondence should be addressed to Erwin Blessing,erwin blessing@yahoo.de
Received 12 March 2011; Revised 12 April 2011; Accepted 15 April 2011
Academic Editor: Tˆ ania Fr¨ ode
Copyright © 2011 Qianxing Zhou et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Aim. Thrombin not only plays a central role in thrombus formationand platelet activation, but also in induction of inﬂammatory
processes. Activated factor X (FXa) is traditionally known as an important player in the coagulation cascade responsible for
thrombin generation. We assessed the hypothesis that rivaroxaban, a direct FXa inhibitor, attenuates plaque progression and
promotes stability of advanced atherosclerotic lesions in an in vivo model. Methods and Results. Rivaroxaban (1 or 5mg/kg body
weight/day) or standard chow diet was administered for 26 weeks to apolipoprotein E-deﬁcient mice (n = 20 per group) with
already established atherosclerotic lesions. There was a nonsigniﬁcant reduction of lesion progression in the high-concentration
group, compared to control mice. FXa inhibition with 5mg Rivaroxaban/kg/day resulted in increased thickness of the protective
ﬁbrous caps (12.3 ± 3.8μmv e r s u s1 0 .1 ± 2.7μm; P<. 05), as well as in fewer medial erosions and fewer lateral xanthomas,
indicating plaque stabilizing properties. Real time-PCR from thoracic aortas revealed that rivaroxaban (5mg/kg/day) treatment
reduced mRNA expression of inﬂammatory mediators, such of IL-6, TNF-α,M C P - 1 ,a n dE g r - 1( P<. 05). Conclusions.C h r o n i c
administration of rivaroxaban does not aﬀect lesion progression but downregulates expression of inﬂammatory mediators and
promotes lesion stability in apolipoprotein E-deﬁcient mice.
1.Introduction
Rivaroxaban (Bayer AG, Germany) is a novel oral direct
factor Xa (FXa) inhibitor not only of free FXa, but also
of prothrombinase complex and clot bound FXa activity. It
displays potent antithrombotic eﬀects in a variety of in vivo
venous and arterial thrombosis models [1].
In 2008, rivaroxaban received approval in the European
Union and in Canada for the prevention of VTE in adult
patients undergoing elective total hip or knee replacement
surgery. Two major clinical studies evaluated rivaroxaban
in patients with atrial ﬁbrillation [2] and in the treatment
of venous thromboembolism [3]. Besides its classical role
in the prevention or treatment of thromboembolic diseases,
rivaroxaban was also evaluated in a phase II clinical trial in
patients stabilized after acute coronary syndromes (ACS).
The risk of clinically signiﬁcant bleeding was increased
in a dose-dependent manner, as compared with placebo.
Factor Xa inhibition was associated with a trend reduction
of the primary eﬃcacy endpoint of death, myocardial
infarction, stroke, or severe recurrent ischaemia requiring
revascularisation. Regarding the main secondary eﬃcacy
endpoint,rivaroxabansigniﬁcantly reducedtherateofdeath,
myocardial infarction, or stroke [4]. The phase III study
Atlas-ACS-TIMI 51 in patients after ACS is ongoing.
Atherosclerosis is a progressive, inﬂammatory disease
characterized by the accumulation of lipids and ﬁbrous
elements in the arteries. Although advanced lesions can
grow suﬃciently large to block blood ﬂow, the most
important clinical complication is an acute occlusion due2 Mediators of Inﬂammation
to thrombus formation, resulting in myocardial infarction
or stroke. Often, thrombus formation is associated with
rupture or erosion of unstable atherosclerotic lesion, as
the prothrombotic content of necrotic cores get exposed to
circulating thrombocytes [5, 6].
The intrinsic and the extrinsic pathway of the coag-
ulation cascade converge at the activation of factor X to
Xa. Active factor Xa hydrolyzes and activates prothrombin
to thrombin. Increasing evidence showed that coagulation
factors such as thrombin participate in atherosclerotic heart
disease in ways that do not directly involve thrombus
formation such as signalling through protease-activated
receptors [7]. Previous experiments in our laboratory
demonstratedthatximelagatran, adirectthrombininhibitor,
reduced lesion progression and promoted plaque stability in
apolipoprotein E-deﬁcient mice [8]. Data on the vascular
eﬀects of new generation direct FXa inhibitors are very
limited.
This prompted us to investigate whether administration
of the direct factor Xa inhibitor rivaroxaban attenuates pro-
gression and promotes stability of advanced atherosclerotic
lesions in hyperlipidemic apolipoprotein E-deﬁcient mice.
2.Materialsand Methods
2.1. Animals and Drug Treatment. Sixty 26-week-old female
apoliprotein E-deﬁcient mice (Charles River Laboratories,
Wilmington, USA, strain name B6.129P2Apoetm1Unc/Crl)
with already established advanced atherosclerotic lesions in
the innominate artery were kept within the animal care
facility of the University of Heidelberg. Sixty mice were
randomized to 3 groups (20 mice per group): one group
received standard chow diet (control group), one group
received chow diet supplemented with 1mg rivaroxaban/kg
bodyweight/day (low-concentration group), and one group
a chow diet, supplemented with 5mg rivaroxaban/kg body-
weight/day (high-concentration group) for 26 weeks. The
housing and care of animals and all the procedures done in
the study were performed in accordance with the guidelines
and regulations of the local Animal Care Committee of the
University of Heidelberg. The investigation conforms to the
Guidefor the Care and Use ofLaboratory Animals published
by the USNational Institutes of Health(NIH publicationno.
85–23, revised 1996).
2.2. Animal Sacriﬁce and Preparation of Plasma and Tis-
sue. Mice were euthanized at 52 weeks without fasting
before anaesthesia. Mice were heavily sedated (Xylazin and
Ketamin), blood was collected in citrated (5 mice per group)
orheparin(5micepergroup)syringesfromtheinferiorvena
cava and saved in citrated or heparin vials. Blood samples
were centrifuged at 3000rpm for 10min at approximately
4◦C to obtain plasma, which was stored at −20◦Cu n t i l
analysis. Mice were then perfused with 10mL phosphate
buﬀered saline at physiological pressure via left ventricle,
and thoracic aortas were ligated distal of the left subclavian
artery and removed for subsequent analysis of candidate
g e n e sb yR T - P C Ro rf o rt r a n s c r i p t i o nf a c t o ra n a l y s i sb yg e l
shift assays. Then, mice were perfused with 4% buﬀered
formalin, at physiological pressure via the left ventricle.
Finally, innominate arteries were embedded in paraﬃna n d
serially sectioned (5μm). Every ﬁfth section was stained with
Movat’s staining.
2.3. Determination of Plasma Lipid Levels and Rivaroxaban
Concentration. Plasma concentrations of total cholesterol,
HDLand LDLcholesterol,andtriglycerideswere determined
enzymatically in heparinized plasma with an automatic
analyzer ADVIA 2400 Chemistry Systems (Bayer AG, Ger-
many). Total cholesterol and triglycerides were measured
using the COD-PAP and GPO-PAP method (cholesterol
oxidase/glycerolphosphate oxidase coupled to phenol and 4-
aminophenazone) and HDL and LDL cholesterol were mea-
sured using commercial available kits (Bayer AG, Germany).
Rivaroxaban concentrations were determined in citrated
plasma by Bayer AG, Germany.
2.4. Evaluation of Plaque Composition and Lesion Size. Two
independent investigators who were blinded to the study
protocol evaluated each section for characteristic features of
plaque instability. These included thickness of the ﬁbrous
cap (thin ﬁbrous cap was deﬁned as 3 or fewer cell layers),
size of the necrotic core (a large necrotic core was deﬁned as
occupyingmorethan1/3ofthetotallesionarea),intraplaque
hemorrhage (deﬁned as the presence of red blood cells
independent of microvessels), calciﬁcation (deﬁned on the
basis of positive staining with the van Kossa stain), presence
of cholesterol crystals, medial erosion (deﬁned as inﬁltration
of plaque tissue into the media), and lateral xanthomas
(deﬁnedasthepresenceofaggregatesofmacrophage-derived
foam cells situated on the lateral margins of the plaques).
These were recorded as binary outcomes and the frequency
for each group was determined.
Each cross-sectional area of each plaque was analyzed
using computer-assisted morphometry (Image Pro, Media
Cybernetics, Silver Spring, USA). Maximum lesion area,
maximum lesion thickness, maximum percent stenosis,
maximum area of the necrotic core and minimal thickness of
the ﬁbrous cap and of the media per animal were identiﬁed
and used for subsequent statistical comparison between the
groups.
2.5. Immunohistochemistry. Tissue sections of the innomi-
nate artery adjacent to the sites of maximum lesion area were
dewaxed and rehydrated. Endogenous peroxidase activity
was inhibited by incubation with peroxoblock (Invitro-
gen, Karlsruhe, Germany). Detection of macrophages was
performed by using monoclonal rat anti-mouse antibody
(anti-Mac-2, Burlington, Canada), expression of smooth
muscle alpha actin using a speciﬁc rabbit antibody (Dianova
GmbH, Hamburg, Germany) according to the manufac-
turer’s protocols. Anti-Mac-2 and actin were incubated
for one hour at room temperature. Sections were then
incubated with biotinylated secondary antibodies, rinsed
3x with PBS and incubated for 10min with streptavidin
at room temperature. AEC-chromogen substrate (Zytomed
SystemsGmbH,Berlin,Germany) wasusedforvisualization.
The extent of positive staining within the lesions wasMediators of Inﬂammation 3
Table 1: Weight, rivaroxaban plasma concentrations, and lipids levels.
Control Low High P
Weight (g) 30.5 ± 3.4 29.4 ± 4.1 27.3 ± 3.5
∗P <. 01
Rivaroxaban concentration (ng/mL) <2.0 6.5 ± 1.5 24.2 ± 9.3
∗P <. 01
Total cholesterol (mg/dL) 208.6 ± 68.0 218.8 ± 67.1 231.9 ± 55.0 ns
LDL cholesterol (mg/dL) 194.6 ± 68.5 203.4 ± 63.2 219.0 ± 51.9 ns
HDL cholesterol (mg/dL) 6.0 ± 2.1 4.9 ± 2.6 5.4 ± 2.9 ns
Triglycerides (mg/dL) 40.0 ± 16.8 52.0 ± 15.0 36.7 ± 12.0 ns
∗high concentration versus control group.
normalized tomaximumlesionareausing computer-assisted
morphometry (Nikon GmbH, D¨ usseldorf, Germany).
2.6. Real-Time PCR Analysis. Total RNA from thoracic
aortas was extracted and determined by absorbance at
260nm. RNA was reverse transcribed with revert aid ﬁrst
strand synthesis kit (Fermentas, St. Leon-Rot, Germany).
Real-time PCR was performed for each gene on a light cycler
usinghybridizationprobesandprimersdesignedontheUni-
versal Probe Library (Roche Diagnostics GmbH, Mannheim,
Germany). All procedures were performed according to
manufacturer’s protocol. Relative levels of gene expression
were calculated as previously reported [9].
2.7. Statistical Analysis. All data are expressed as mean ±
S.E.M. Signiﬁcant diﬀerences between means in plasma lipid
levels, serum rivaroxaban levels were determined with one-
factor ANOVA. Analysis of plaque morphometry and areas
of positive immunohistochemistry staining were determined
by using one-factor ANOVA. For evaluation of plaque
morphology, groups were compared using χ2 test. P values
≤.05 were considered statistically signiﬁcant.
3.Results
3.1. Body Weights, Lipid Levels, and Rivaroxaban Plasma
Concentrations. One mouse out of the control group died
during the study. All other mice remained healthy. In
particular, no apparent bleeding was observed. At the time
of sacriﬁce, mice treated by the high dose of rivaroxaban
showed slightly, yet signiﬁcant lower body weights compared
to the control group (Table 1).
There were no signiﬁcant diﬀerences in total cholesterol,
LDL-cholesterol, HDL-cholesterol, and total triglycerides
levels among the groups (Table 1). Therefore, the observed
eﬀects in the present study are not related to any lipid-
modifying eﬀects of rivaroxaban. Plasma levels of rivarox-
aban were 24.2 ± 9.3ng/mL (average ± SD) in the high-
concentration group and 6.2 ± 1.5ng/mL (average ± SD) in
thelow-concentrationgroup(n = 5ineachgroup)(Table 1).
3.2. Lesion Progression and Plaque Composition. Morphome-
tric analysis of brachiocephalic arteries revealed that chronic
administration ofrivaroxabaninthechow dietover26weeks
did not signiﬁcantly alter progression of atherosclerotic
Table 2: Morphologic lesion analysisA. Brachiocephalica.
Control Low High P
(n = 19) (n = 20) (n = 20)
Thin ﬁbrous cap 16/19 17/20 17/20 ns
Large necrotic core 11/19 13/20 11/20 ns
Medial erosion 15/19 12/20 9/20
∗P <. 05
Calciﬁcation 12/19 13/20 12/20 ns
Cholesterol crystals 19/19 19/20 20/20 ns
Lateral xanthoma 7/19 3/20 1/20
∗P <. 05
Hemorrhage 11/19 7/20 6/20 ns
∗high concentration versus control group.
plaques in apolipoprotein E-deﬁcient mice (Figure 1). How-
ever,administration ofthehighconcentrationofrivaroxaban
increased thickness of the protective ﬁbrous caps (12.3 ±
3.8μmv e r s u s1 0 .1 ± 2.7μm of the control group; P<. 05).
Moreover, there was a signiﬁcant reduction in the presence
of medial erosions and lateral xanthomas in the rivaroxaban
mice (5mg/kg/day), as compared with the control animals
(Table 2). Interestingly, frequency of medial erosions were
also reduced in our previous experiments with the direct
thrombin inhibitor melagatran [8].
Analysis of plaque composition by immunohistochem-
istry showed a nonsigniﬁcant decrease of staining against
smooth muscle alpha actin (P = .06) in the high
dose rivaroxaban group (Figure 2). Staining against smooth
muscle alpha actin was predominantly located within the
ﬁbrous cap. There was no statistical signiﬁcant diﬀerence in
staining against Mac-2 between the three groups (Figure 2).
Representative lesion morphology is shown in Figure 4.
3.3. Expression of Inﬂammatory Cytokines in Aortic Tissue.
Chronic administration of both concentrations of rivaroxa-
ban signiﬁcantly decreased mRNA expression of IL-6, TNF-
α,M C P - 1 ,a n dE g r - 1i na o r t i ct i s s u eo ft r e a t e dm i c e ,a s
compared to the control group (Figure 3). Data in Figure 3
indicate the fold increase of mRNA expression of the aortic
tissue in relation to that of control mice. Surprisingly, only
mice receiving the low, but not the high dose of rivaroxaban,
showed a signiﬁcant reduction of mRNA expression of IFN-
γ. There were no signiﬁcant diﬀerences in respect of tissue
factor expression between the three groups (Figure 3).4 Mediators of Inﬂammation
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Figure 1: Morphometric analysis data. Administration of rivaroxaban in the chow diet over 26 weeks did not signiﬁcantlyreduce maximum
lesion area (a), percentage of stenosis (b), lesion thickness (c), necrotic core area (e), or percentage of the necrotic core area in relation to
total lesion area (f).Thickness ofthe protective ﬁbrous cap was signiﬁcantlylarger in mice, receiving the high-concentration rivaroxaban, as
compared to control mice ((d), P<. 05). Data represent mean ± SEM. ∗P<. 05.Mediators of Inﬂammation 5
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Figure 2: Immunohistochemistry. Immunohistochemistry staining with antibodies against Mac-2 (a, c), demonstrating presence of
macrophages within an advanced lesion. Mac-2 was predominantely located within the necrotic cores (arrows) and did not signiﬁcantly
diﬀer between the three experimental groups.Stainingfor alphaactin (b, d) waspredominantely located withinthe ﬁbrous cap(arrows)and
showed a trend reduction (P = .06) in the high-concentration group, as compared to the control group. Both representative cross-sections
(c, d) were from mice that received high-concentration of rivaroxaban (5mg/kg/day). Error bars represent mean ± SEM.
4.Discussion
The present study demonstrates that long-term administra-
tionoftheoraldirect factorXainhibitorrivaroxaban reduces
expression of proinﬂammatory mediators, such as IL-6,
TNF-α, MCP-1, and Egr-1 in aortic tissue of apolipopro-
tein E-deﬁcient mice. Furthermore, rivaroxaban enhances
thickness of the protective ﬁbrous caps and reduces presence
of medial erosions and lateral xanthomas, thus promoting
lesion stability in this model of advanced atherosclerotic
disease. However, the reduction of progression of lesion size
did not achieve statistical signiﬁcance.
Factor Xa plays a central role in the coagulation cascade,
linking the extrinsic and intrinsic pathways by catalyzing
the conversion of prothrombin to thrombin on vascular
cell surfaces [10]. Factor Xa elicits various and complex
signalling events on a wide range of cell types, by activating
protease-activated receptors-1 (PAR-1) and PAR-2. Factor
Xa and thrombin share PAR-1, the main receptor for
thrombin as a downstream cellular receptor [11]. PAR-2
expression is enhanced in human coronary atherosclerotic
lesions[12].MediatedthroughPAR-2,FXaacts asa powerful
chemoattractant for ﬁbroblasts and contributes to ﬁbroblast
diﬀerentiationinto myoﬁbroblasts [13]. Interest in FactorXa
signalling was ignited after the realization that PAR-2, rather
than PAR-1, acts as a key player in the progression of a wide
pattern of pathologies at the ﬁbroproliferative interface [13–
16].
Atherosclerosis is not only related to the formation and
progression of atherosclerotic plaques, but also considered
a systemic inﬂammatory disease, which is modulated by
genetic and environmental risk factors. Sustained inﬂamma-
tion can lead to plaque rupturea n dt h r o m b u sf o r m a t i o n
with subsequent ischemia and myocardial infarction [5, 6].
In recent studies, Factor Xa has been found to trigger acute
inﬂammatory responses in vivo [17–19]a n din vitro [20–
22]. In endothelial cells, Factor Xa leads to the activation
of nuclear factor κB( N F - κB), the release of IL-6, IL-
8, and monocyte chemotactic protein-1 (MCP-1), which
contributes to leukocyte recruitment [20–22]. Most of these6 Mediators of Inﬂammation
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Figure 3: RT-PCR of inﬂammatory mediators. Chronic administration of both concentrations of rivaroxaban signiﬁcantlydecreased mRNA
expression of MCP-1 (b), IL-6 (c), TNF-α (d), and Egr-1 (f) in aortic tissue of rivaroxaban-treated mice, as compared to the control
group. Mice receiving the low (1mg/kg/day), but not the high dose (5mg/kg/day) of rivaroxaban, showed a signiﬁcant reduction of mRNA
expression of IFN-γ (e). There were no signiﬁcant diﬀerences in respect of tissue factor expression between the three groups (a). Data
represent fold increase of mRNA expression as compared to the control group. Data represent mean ± SEM. ∗P<. 05.Mediators of Inﬂammation 7
(a) Lesion thickness (b) Medial erosion
(c) Cap thickness (d) Lateral xanthoma
Figure 4: Representative lesion morphology. Representative brachiocephalic artery from a mouseafter chronic administrationof rivaroxaban
(5mg/kg/day). Movat’s pentachrome staining shows features of an advanced but rather stable atherosclerotic lesion with a small necrotic
cores and a thick protective ﬁbrous cap (a). In contrast, a lesion from a mouse from the low-concentration group (1mg/kg/day) shows a less
stable lesion with a large necrotic core, partially eroding into the media (arrow, (b)). (c) shows a representative example of a control mouse,
where the ﬁbrous cap (arrow), separating the necrotic core from the lumen, is reduced to few cell layers. Lateral xanthomas(arrow), deﬁned
as the presence of aggregates of macrophage-derived foam cells, situated on the lateral margins of the plaques were observed signiﬁcantly
more frequently in control mice (d). Bar indicates 100μm. Data are presented as mean ± SEM.
responses are mediated via PAR2 activation although some
studies showed minor involvement of PAR1 [21, 23].
Coagulation is closely united with inﬂammatory sig-
nalling pathways [24, 25]. Several studies have shown that
anticoagulant treatment not only diminishes activation of
coagulation but also inhibits inﬂammation, indicating the
extensive interplay between these processes. However, eﬀects
of rivaroxaban on lesion composition were, at least in part,
unrelated to its antithrombotic activity. The expression of
tissue factor, a potent activator of the extrinsic coagula-
tion cascade, was not diﬀerent in thoracic aortas from
rivaroxaban treated compared with control mice. Signiﬁcant
thrombus formation was neither observed in the present
study,norinourpreviousstudiesofadvancedatherosclerotic
lesions in the same model, possibly due to a high ﬁbrinolytic
activity in mice [26].
Rivaroxaban is a small synthetic molecule able to inhibit
free Factor Xa clot-bound and prothrombinase-bound
Factor Xa. Unlike indirect Factor Xa inhibitors, the eﬀect of
rivaroxaban does not require the presence of antithrombin
[27].
Factor Xa is also known to promote mitogenesis of
serveral cell lines, including vascular smooth muscle cells
(VSMC) [28–30]. Several studies demonstrated that inhi-
bition of Factor Xa reduces VSMC proliferation [31], and
restenosis after balloon angioplasty [31–35]. At the molec-
ular level, wound healing and ﬁbrosis share similar mech-
anisms, including ﬁbroblast migration, proliferation and
subsequent diﬀerentiation into myoﬁbroblasts that typically
express α-SM actin [36]. In renal interstitial ﬁbrosis, there
is a correlation between α-SM actin and PAR-2 expression
[37]. In the present study, there was also a trend towards
reduced staining against α-smooth muscle actin in lesions
of rivaroxaban treated mice, suggesting a potential eﬀect
of rivaroxaban reducing restenosis after ballon angioplasty,
through its antiproliferative properties.8 Mediators of Inﬂammation
Interestingly, in contrast to our previous observations
withsimvastatin[38],frequencyofintraplaquehaemorrhage
was not reduced by administration of rivaroxaban. It is
possible that in regard to plaque haemorrhage, plaque-
stabilizing eﬀects of Factor Xa inhibition were counteracted
by its anticoagulatory properties, resulting in comparable
patterns of erythrocyte deposition in otherwise more stable
lesions.
Plasma levelsofrivaroxaban were ratherlowinourstudy.
Bioavailability of rivaroxaban is poor in mice, compared
to rats and other species. Therefore, administration of a
higher dose of the drug via the chow diet would not have
necessarily resulted in signiﬁcantly higher plasma concentra-
tions. It seems possible that higher plasma concentrations
of rivaroxaban might have translated not only to anti-
inﬂammatory and lesion stabilizing eﬀects, as observed in
the present study, but also to a signiﬁcant reduction of
lesion progression. The rationale of using the present animal
model was that long-term exposure to the drug in the
genetically altered hyperlipidemic mice enables not only
evaluation of lesion progression, but also, more relevant,
of plaque composition. It also allows an, at least indirect
comparison, between direct Factor Xa inhibition and direct
thrombin inhibition, as evaluated by us in a previous study
[8].
In our study, long-term administration of rivaroxaban
(5mg/kg/d) signiﬁcantly decreased mRNA expression of
Egr-1, IL-6, TNF-α, and MCP-1 in mouse aortic tis-
sue, clearly demonstrating anti-inﬂammatory properties of
Factor Xa inhibition. Mice, deﬁcient in MCP-1 or its
receptor CCR2, had signiﬁcantly reduced atherosclerotic
lesions, suggesting that MCP-1/CCR2 interaction has a
role in monocyte recruitment in atherosclerosis [39, 40].
Although monocyte recruitment is an important proinﬂam-
matory event in atherogenesis, numbers of macrophages,
as assessed by immunohistochemistry, were not reduced
by rivaroxaban treatment in the present study. Further
studies are needed to evaluate whether Factor Xa inhibition
reduces activity of macrophages rather than the actual
number of inﬂammatory cells in advanced atherosclerotic
lesions.
5.Conclusion
In conclusion, our study demonstrates that chronic admin-
istration of rivaroxaban can exert anti-inﬂammatory eﬀects,
stabilizing lesions in a modelof advanced atheroscleroticdis-
ease. Direct Factor Xa inhibitors might emerge as potential
therapeutic tool in patients with established atherosclerotic
disease.
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